GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pluri PLUR · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.18

-4.84%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Pluri

From its filings with the US Securities and Exchange Commission

SEC filings

Pluri is based in Haifa and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker PLUR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 June 2026, it reported revenue of $1.0m and a net loss of $23.8m. At that date it held total assets of $24.9m and shareholders' equity of −$23.0m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
10 Dec 2007
Employees
123
Head office
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Incorporated in
NV
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Alejandro Weinstein M.Non-Executive Chairman of the Board
  • Mr. Yaky YanayPresident, Chief Executive Officer, Director, since 2006$741,479
  • Mr. Zalman AbermanVice Chairman of the Board, since 2005$148,170
  • Mrs. Liat ZaltsChief Financial Officer, Treasurer
  • Mr. Eitan AjchenbaumDirector
  • Mr. Alexandre WeinsteinDirector
  • Mr. Rami LeviIndependent Director$60,097
  • Ms. Maital Shemesh-RasmussenIndependent Director$63,546

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Pluri Inc has a clinical stage focus on cell therapy development.
  • The company operates in the Health Care sector within Biotechnology.
  • Pluri Inc has a specific product pipeline including PLX-PAD and PLX R18.

Weaknesses

  • The company's products are still in clinical-stage development.
  • The firm relies on a three dimensional (3D) process for cell expansion.
  • Pluri Inc has limited employee count of 123.

Opportunities

  • The company's PLX products target multiple indications including cardiovascular and orthopedic diseases.
  • Pluri Inc's technology uses a synthetic scaffold for cell growth.
  • The firm's focus on clinical-stage development may lead to future market entry.

Threats

  • The company's products are in clinical-stage development, which carries inherent risks.
  • Pluri Inc's operations are limited to specific therapeutic areas.
  • The firm's reliance on a single cell therapy technology may pose risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.